Akesobio: Trading Debut, Valuation Scenario Analysis
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
471 Views
Akesobio (康方生物) IPO Trading: Action Post Near Zero Allocation
Akesobio, a China-based biotech company, raised USD 314 million at HKD 16.18 per share. The deal has attracted strong demands from both retail...
426 Views
Akesobio IPO: Valuation Insights
Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...
475 Views
Akesobio (康方生物) IPO: Expect near Zero Allocation
Akesobio launched book building to raise up to USD 333 million to list in Hong Kong. In our previous note, we discussed that the company features...
578 Views
Akesobio IPO Initiation: The Tough Get Going
Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology,...
463 Views